Are Insurers Finding a Way Around Obamacare Preexisting-Conditions Protections?

HIV advocates worry some insurers are steering patients away from their plans by offering limited treatment options and insufficient information.

NEW YORK, NY - JUNE 27: A sign for free HIV testing is seen outside a Walgreens pharmacy in Times Square on June 27, 2012 in New York City. June 27 is National HIV Testing Day and the Centers for Disease Control and Prevention is rolling out a new program offering free rapid HIV testing in pharmacies in 24 cities and rural communities.
National Journal
Sophie Novack
Add to Briefcase
Sophie Novack
Nov. 7, 2013, 12:49 p.m.

The Af­ford­able Care Act pro­hib­its in­surers from deny­ing cov­er­age to in­di­vidu­als with preex­ist­ing con­di­tions, but some com­pan­ies may be lim­it­ing their pre­scrip­tion-drug of­fer­ings to steer HIV pa­tients to oth­er plans.

“We’re see­ing policies in place by in­sur­ance com­pan­ies that cer­tainly look like they are in­ten­ded to make plans look less at­tract­ive to pa­tients with HIV,” said John Peller, vice pres­id­ent of policy at AIDS Found­a­tion of Chica­go.

There are two main con­cerns with the policies in ques­tion: that com­pan­ies are not of­fer­ing single-tab­let re­gi­mens (STRs) for HIV pa­tients in their Qual­ity Health Plan for­mu­lar­ies (the list of pre­scrip­tion medi­cines covered), and that there is a lack of trans­par­ency as far as what the plans of­fer to in­di­vidu­als with the dis­ease.

Ad­vocacy groups are ob­serving this across a num­ber of ma­jor in­sur­ance com­pan­ies in a large num­ber of states.

The HIV Health Care Ac­cess Work­ing Group (HH­CAWG), a co­ali­tion of na­tion­al HIV health policy ad­voc­ates, has sent let­ters to in­sur­ance com­pan­ies and to Health and Hu­man Ser­vices Sec­ret­ary Kath­leen Se­beli­us re­gard­ing the is­sue.

“We’re mak­ing sure that for­mu­lar­ies are ro­bust, and [in­sur­ance com­pan­ies] are not util­iz­ing man­age­ment tech­niques — like tier­ing or pri­or ap­prov­al — that cre­ate un­fair or un­due bur­dens on people to meet their stand­ard of care,” says Robert Gre­en­wald, dir­ect­or of the Cen­ter of Health Law and Policy In­nov­a­tion at Har­vard Law School, and a co­chair of HH­CAWG. Gre­en­wald is the main in­di­vidu­al be­hind the ef­fort, and point per­son on the let­ters.

STRs are cru­cial to qual­ity HIV treat­ment, al­low­ing pa­tients to take only one pill a day. STRs “are the most fre­quently taken HIV drugs, and have ab­so­lutely re­vo­lu­tion­ized care for people with HIV,” Peller says. “There is strong evid­ence that shows someone with HIV on a single-tab­let re­gi­men is more likely to stick to their re­gi­men.” Stud­ies show that STRs re­duce hos­pit­al­iz­a­tions by 23 per­cent and over­all med­ic­al costs by 17 per­cent.

“The hope is to call at­ten­tion to this, giv­en that com­pounds are very ef­fect­ive and not more costly than their com­pon­ent parts,” Gre­en­wald says. He says that part of the reas­on com­pan­ies are not of­fer­ing STRs is the way that Cen­ters for Medi­care and Medi­caid Ser­vices guidelines to is­suers are cur­rently writ­ten — dif­fer­ent dosages, con­cen­tra­tions, and de­liv­ery meth­ods of a drug are con­sidered the same if they have the same com­pon­ents.

Ad­voc­ates worry not only that the STRs are not avail­able on some plans, but also that in­form­a­tion re­gard­ing what is avail­able is ex­tremely dif­fi­cult to find.

“Some com­pan­ies post a sub­set of for­mu­lar­ies and not the whole one,” says An­drea Weddle, ex­ec­ut­ive dir­ect­or of the HIV Medi­cine As­so­ci­ation and an­oth­er co­chair of HH­CAWG. “It can be mis­lead­ing and makes it dif­fi­cult for people with more chron­ic con­di­tions to make sure their spe­cif­ic medi­cine is avail­able.” Weddle says in­form­a­tion is highly vari­able from state to state and in­surer to in­surer, in terms of how much trans­par­ency there is in the plans offered.  

“I do think we have some con­cerns that [plans] lack trans­par­ency,” Gre­en­wald con­curs. “If people don’t see their med­ic­a­tions, see them only avail­able with cost-shar­ing that is highly-tiered, or oth­er man­age­ment tech­niques to make it dif­fi­cult to ac­cess the care [pa­tients] want — if that is seen hap­pen­ing tar­geted at any con­di­tion — that would be a dis­crim­in­at­ory prac­tice.”

Ad­voc­ates say it is too soon to tell wheth­er these policies are in­ten­ded to steer away HIV pa­tients, and the is­sue falls in­to a bit of a gray area as far as an­ti­discrim­in­a­tion pro­tec­tions in the ACA. HHS reg­u­la­tions al­low plans some flex­ib­il­ity, but they are re­quired to cov­er at least one drug in every class, as well as the num­ber of drugs in the state bench­mark plan. 

“If it ap­pears a plan is de­signed, or mar­ket­ing is spe­cific­ally de­signed, to dis­cour­age en­roll­ment, that would rise to the level [of dis­crim­in­a­tion],” Gre­en­wald says. “We’re mon­it­or­ing to make sure that doesn’t hap­pen.”

Gre­en­wald says he has already re­ceived some re­sponses to the let­ter from in­sur­ance com­pan­ies, say­ing they ree­valu­ated their cov­er­age and are now plan­ning to in­clude STRs in their plans.

BlueCross Blue­Shield Well­Point re­spon­ded say­ing it would of­fer At­ri­pla — the first HIV re­gi­men in one daily pill — though Well­Point spokes­wo­man Lori McLaugh­lin says this change was already in the works.

“Well­Point af­fil­i­ated plans will all of­fer At­ri­pla,” she wrote in an email. “However, sim­il­ar to our ap­proach in all drug classes, not all HIV drug com­bin­a­tions will be in­cluded on for­mu­lary, just as all com­bin­a­tions are not offered in oth­er drug classes. In most states, spe­cialty drugs are offered on Tier 3 or Tier 4, which re­quires co-in­sur­ance.”

“It’s great,” Gre­en­wald says of the re­sponses he’s re­ceived thus far. “We’ve iden­ti­fied a prob­lem that could have been very ser­i­ous, and there’s some in­dic­a­tion we may be able to re­solve it by watch­ing closely and hold­ing com­pan­ies ac­count­able.”

What We're Following See More »
THE PLAN ALL ALONG?
Manchin Drops Objections, Clearing Way for Spending Deal
1 days ago
THE LATEST

"The Senate standstill over a stopgap spending bill appeared headed toward a resolution on Friday night. Senators who were holding up the measure said votes are expected later in the evening. West Virginia Democrat Joe Manchin had raised objections to the continuing resolution because it did not include a full year's extension of retired coal miners' health benefits," but Manchin "said he and other coal state Democrats agreed with Senate Democratic leaders during a caucus meeting Thursday that they would not block the continuing resolution, but rather use the shutdown threat as a way to highlight the health care and pension needs of the miners."

Source:
UNCLEAR WHAT CAUSED CHANGE OF HEART
Giuliani Out of Running For State
1 days ago
BREAKING

Donald Trump transition team announced Friday afternoon that top supporter Rudy Giuliani has taken himself out of the running to be in Trump's cabinet, though CNN previously reported that it was Trump who informed the former New York City mayor that he would not be receiving a slot. While the field had seemingly been narrowed last week, it appears to be wide open once again, with ExxonMobil CEO Rex Tillerson the current favorite.

Source:
ALSO VICE-CHAIR OF TRUMP’S TRANSITION TEAM
Trump Taps Rep. McMorris Rodgers for Interior Secretary
1 days ago
BREAKING
SHUTDOWN LOOMING
House Approves Spending Bill
2 days ago
BREAKING

The House has completed it's business for 2016 by passing a spending bill which will keep the government funded through April 28. The final vote tally was 326-96. The bill's standing in the Senate is a bit tenuous at the moment, as a trio of Democratic Senators have pledged to block the bill unless coal miners get a permanent extension on retirement and health benefits. The government runs out of money on Friday night.

HEADS TO OBAMA
Senate Approves Defense Bill
2 days ago
THE LATEST

The Senate passed the National Defense Authorization Act today, sending the $618 billion measure to President Obama. The president vetoed the defense authorization bill a year ago, but both houses could override his disapproval this time around.

Source:
×
×

Welcome to National Journal!

You are currently accessing National Journal from IP access. Please login to access this feature. If you have any questions, please contact your Dedicated Advisor.

Login